Neurocognitive And Developmental Disorders

SECTION 1

Historical Context & Motivation

The conceptualization of neurocognitive disorders (NCDs) and neurodevelopmental disorders has undergone dramatic transformation over the past two centuries. Early clinicians grouped all forms of cognitive decline under the blanket term "dementia," a Latin word literally meaning "without mind." Neurodevelopmental conditions such as intellectual disability and autism were similarly conflated under pejorative labels that offered no mechanistic insight. The evolution toward modern diagnostic criteria reflects advances in neuropathology, neuroimaging, molecular genetics, and standardized psychometric testing. Understanding this history is essential because the DSM-5 classification system you will encounter on the USMLE Step 2 directly descends from these iterative refinements, and appreciating the rationale behind current diagnostic categories will help you select the correct answer on exam day.

1906

Alois Alzheimer's Case Report

Alois Alzheimer presents the case of Auguste Deter, describing neurofibrillary tangles and senile plaques at autopsy—the first clinicopathologic correlation for what would become Alzheimer disease.

1943

Kanner Describes Autism

Leo Kanner publishes "Autistic Disturbances of Affective Contact," establishing autism as a distinct clinical entity separate from childhood schizophrenia.

1980

DSM-III Operationalizes Criteria

The DSM-III introduces criterion-based diagnostic sets for organic mental disorders and developmental disorders, emphasizing observable behavior over psychodynamic inference.

2013

DSM-5 Reframes the Categories

The DSM-5 replaces "dementia" with major neurocognitive disorder and introduces mild neurocognitive disorder, while consolidating neurodevelopmental disorders into a unified chapter.

The central clinical question that motivates this entire topic area is: How do we distinguish normal cognitive variation from pathological cognitive decline, and how do we differentiate the many etiologies that produce overlapping clinical presentations? Whether you are evaluating a 72-year-old with progressive memory loss or a 4-year-old with speech delay, the diagnostic approach demands systematic evaluation of cognitive domains, functional status, and underlying etiology. This lesson provides the framework you need to navigate both categories with confidence.

SECTION 2

Core Principles & Definitions

The DSM-5 organizes these conditions into two overarching chapters: Neurocognitive Disorders (NCDs) and Neurodevelopmental Disorders. NCDs encompass acquired cognitive decline from a previous level of functioning—subdivided into major and mild forms—and are further specified by etiology (e.g., Alzheimer disease, vascular, Lewy body, frontotemporal, traumatic brain injury, HIV, substance/medication, Huntington disease, prion disease). Neurodevelopmental disorders, by contrast, manifest in the developmental period and include intellectual disability, autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), specific learning disorders, communication disorders, and motor disorders. The fundamental organizing principles below will anchor your diagnostic reasoning.

Cognitive Domain Assessment

The DSM-5 identifies six key cognitive domains: complex attention, executive function, learning and memory, language, perceptual-motor, and social cognition. Documenting which domains are impaired helps localize pathology and narrow the etiologic differential.

Major vs. Mild NCD

Major NCD (formerly dementia) requires significant cognitive decline plus impaired independence in everyday activities. Mild NCD requires modest decline that does not compromise functional independence.

Etiologic Specification

After establishing the syndrome (major vs. mild), the clinician specifies the presumed etiology (e.g., due to Alzheimer disease, Lewy body disease). This two-step approach mirrors the clinical workflow: first characterize the deficit, then identify the cause.

Neurodevelopmental Onset

Neurodevelopmental disorders by definition emerge during the developmental period, producing deficits in personal, social, academic, or occupational functioning. Diagnosis often requires comparison to developmental norms.

Reversible vs. Irreversible

A critical clinical and exam-relevant distinction: some causes of cognitive decline are potentially reversible (e.g., B₁₂ deficiency, hypothyroidism, normal pressure hydrocephalus, depression). Always exclude these before diagnosing an irreversible NCD.

✦ KEY TAKEAWAY

Think of diagnosing neurocognitive disorders like troubleshooting a computer that has slowed down. First, you determine which functions are impaired (memory? processing speed? graphics?), then you assess how severely performance has degraded (mild slowdown vs. system crash), and finally you investigate the root cause (malware? hardware failure? outdated driver?). The DSM-5 framework follows the same logic: identify the affected cognitive domains, rate severity (major vs. mild), and specify the etiology.

SECTION 3

Visual Explanation — Diagnostic Flowchart

This flowchart illustrates the stepwise diagnostic approach to neurocognitive disorders. Begin by ruling out delirium, then assess cognitive domains, determine if decline from baseline is present, and finally differentiate major NCD from mild NCD based on functional independence.

The algorithm above captures the essential clinical reasoning pathway tested on Step 2. The very first branch point—ruling out delirium—is arguably the highest-yield concept, because delirium is acute, fluctuating, and often reversible, whereas neurocognitive disorders reflect chronic, progressive decline. A classic exam scenario presents an elderly postsurgical patient with acute confusion and inattention; the correct answer is delirium (not Alzheimer disease), and the management centers on identifying and treating the underlying cause (infection, medication side effect, metabolic derangement). Once delirium is excluded, the clinician uses standardized instruments—such as the Montreal Cognitive Assessment (MoCA) or the Mini-Mental State Examination (MMSE)—to quantify cognitive impairment and track progression. The distinction between major and mild NCD hinges not on test scores alone but on whether the patient's functional independence in daily life is compromised.

SECTION 4

Pathophysiology & Mechanisms

Neurocognitive Disorders: Pathologic Mechanisms by Etiology

Each major NCD etiology has a characteristic neuropathologic signature that drives its clinical phenotype. Alzheimer disease (AD), the most common cause of major NCD, is characterized by extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. These pathologic changes follow a predictable topographic progression described by Braak staging, beginning in the entorhinal cortex and hippocampus (producing the hallmark early memory impairment) and spreading to neocortical association areas (producing later executive dysfunction, visuospatial deficits, and language impairment). Lewy body dementia (LBD) features intraneuronal α-synuclein inclusions (Lewy bodies) in cortical and subcortical regions, producing a triad of fluctuating cognition, visual hallucinations, and parkinsonism. A critical clinical pearl: patients with LBD are exquisitely sensitive to antipsychotic medications, which can precipitate severe neuroleptic sensitivity reactions.

Vascular neurocognitive disorder results from cerebrovascular disease—either large-vessel stroke or small-vessel ischemic changes—and classically presents with a stepwise decline and prominent executive dysfunction, with focal neurologic signs on examination. Frontotemporal dementia (FTD) encompasses a group of disorders characterized by focal degeneration of frontal and/or temporal lobes, with the behavioral variant producing early personality change, disinhibition, and apathy often before significant memory impairment—a distinguishing feature from AD. FTD is associated with intraneuronal inclusions of tau, TDP-43, or FUS protein.

Neurodevelopmental Disorders: Mechanisms

Neurodevelopmental disorders reflect disturbances in brain development during the prenatal, perinatal, or early postnatal periods. Intellectual disability (ID) involves deficits in both intellectual and adaptive functioning with onset during the developmental period. Genetic etiologies are common and include Down syndrome (trisomy 21), fragile X syndrome (FMR1 trinucleotide repeat expansion), and phenylketonuria (PAH enzyme deficiency). Autism spectrum disorder (ASD) is now understood to involve altered connectivity patterns—particularly in prefrontal, temporal, and cerebellar circuits—and is highly heritable (concordance in monozygotic twins ranges from 60–90%). ADHD involves dysregulation of catecholamine (dopamine and norepinephrine) neurotransmission, particularly within frontostriatal circuits. This pathophysiology explains why stimulant medications, which increase catecholamine availability, are first-line pharmacotherapy.

This diagram summarizes the key neuropathologic proteins, affected brain regions, and hallmark clinical features for the four major NCD etiologies (top row) and the three most frequently tested neurodevelopmental disorders (bottom row). Each card highlights the molecular or circuit-level mechanism that drives the clinical phenotype.

SECTION 5

Detailed Classification & Clinical Features

Neurocognitive Disorders — Etiologic Subtypes

Comparison of major NCD etiologies tested on USMLE Step 2

Etiology	Key Clinical Features	Distinguishing Clue	First-Line Treatment
Alzheimer disease	Insidious onset; progressive short-term memory loss → later language, visuospatial, executive deficits	Early episodic memory impairment; hippocampal atrophy on MRI; Aβ₄₂↓ and p-tau↑ in CSF	Cholinesterase inhibitors (donepezil, rivastigmine, galantamine); memantine for moderate-to-severe
Lewy body dementia	Fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behavior disorder, parkinsonism	Severe neuroleptic sensitivity; DaT scan shows decreased dopamine transporter uptake	Cholinesterase inhibitors; AVOID typical antipsychotics (use quetiapine or pimavanserin with caution)
Vascular NCD	Stepwise deterioration; executive dysfunction; gait abnormalities; pseudobulbar affect	Temporal relationship to cerebrovascular events; white matter changes on neuroimaging	Control vascular risk factors (HTN, DM, hyperlipidemia); no FDA-approved specific therapy
Frontotemporal dementia	Behavioral variant: personality change, disinhibition, apathy; Language variant: progressive aphasia	Onset typically before age 65; frontal/temporal atrophy; relative sparing of memory early	SSRIs for behavioral symptoms; no disease-modifying therapy; supportive care
Normal Pressure Hydrocephalus	Classic triad: gait disturbance ("magnetic gait"), urinary incontinence, dementia	Ventriculomegaly out of proportion to cortical atrophy; improvement after large-volume LP	Ventriculoperitoneal (VP) shunt — potentially reversible
Prion disease (CJD)	Rapidly progressive dementia, myoclonus, psychiatric symptoms, ataxia	EEG: periodic sharp-wave complexes; MRI: cortical ribboning (DWI); CSF 14-3-3 protein; RT-QuIC assay	No effective treatment; supportive/palliative care; fatal within ~1 year

Neurodevelopmental Disorders — Key Features

Key neurodevelopmental disorders tested on USMLE Step 2

Disorder	Core Features	Diagnostic Criteria Highlights	Management
Intellectual Disability	Deficits in intellectual functions (reasoning, problem-solving, abstract thinking) AND adaptive functioning (conceptual, social, practical domains)	Onset during developmental period; severity based on adaptive functioning, not IQ alone; IQ < 70 is a guide, not a cutoff	Early intervention programs; special education; behavioral therapy; treat comorbid psychiatric conditions
Autism Spectrum Disorder	Persistent deficits in social communication/interaction PLUS restricted, repetitive patterns of behavior, interests, or activities	Symptoms present in early developmental period (may not fully manifest until social demands exceed capacity); specify severity level (1, 2, or 3)	Applied behavior analysis (ABA); speech-language therapy; social skills training; no FDA-approved medication for core symptoms
ADHD	Persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development	Several symptoms present before age 12; present in ≥ 2 settings; specify presentation (inattentive, hyperactive-impulsive, combined)	First-line: stimulants (methylphenidate, amphetamine salts); second-line: atomoxetine, guanfacine, clonidine; behavioral therapy
Tourette Disorder	Multiple motor tics AND at least one vocal tic (not necessarily concurrent); onset before age 18	Tics present for > 1 year; commonly comorbid with ADHD and OCD; tics wax and wane	Behavioral therapy (CBIT); if severe: fluphenazine, pimozide, aripiprazole; alpha-agonists for mild tics + comorbid ADHD
Specific Learning Disorder	Difficulties in reading (dyslexia), math (dyscalculia), or written expression despite adequate instruction and intelligence	Symptoms persist ≥ 6 months despite targeted intervention; academic skills substantially below age expectations	Individualized education plans (IEP); specialized tutoring; assistive technology; no pharmacologic treatment

⚡ HIGH-YIELD EXAM PEARL

When a question stem describes an elderly patient with a combination of gait instability, urinary incontinence, and cognitive decline, immediately consider normal pressure hydrocephalus (NPH)—the classic "wet, wobbly, and wacky" triad. This is one of the few reversible causes of dementia, treated with VP shunt placement.

SECTION 6

Worked Clinical Example

Clinical Vignette: Differentiating Major NCD Etiologies

Step 1 — Read the Stem CarefullyA 74-year-old woman is brought to the clinic by her daughter, who reports that over the past 18 months her mother has become increasingly forgetful—missing appointments, repeating the same questions, and misplacing household items. She recently got lost driving to a familiar grocery store. She now requires reminders to take her medications and occasional help with finances. Physical examination is unremarkable, and neurological exam shows no focal deficits. MMSE score is 19/30 with particular deficits in recall and orientation.

Step 2 — Rule Out DeliriumThe onset is insidious (18 months), not acute. There is no fluctuation in consciousness described, and attention (assessed by MMSE) is relatively preserved. There is no evidence of acute medical illness or medication change precipitating the symptoms.

Delirium excluded — chronic, progressive course

Step 3 — Assess Cognitive Domains AffectedThe predominant deficits are in learning and memory (repeating questions, forgetting appointments, poor recall on MMSE) and perceptual-motor function (getting lost while driving—suggests visuospatial impairment). Executive function may also be impaired (difficulty managing finances).

Step 4 — Determine Severity (Major vs. Mild NCD)The patient now requires assistance with instrumental activities of daily living (medication management, finances, driving). This represents loss of functional independence in daily activities.

Major NCD — functional independence is compromised

Step 5 — Specify the EtiologyThe insidious onset, progressive course, early and prominent episodic memory impairment, absence of focal neurological signs, and absence of the hallmark features of other etiologies (no visual hallucinations or parkinsonism → rules out Lewy body; no stepwise course → rules out vascular; no early personality change or disinhibition → rules out FTD) all point to Alzheimer disease as the most likely etiology. The MMSE score of 19/30 is consistent with mild-to-moderate severity.

Diagnosis: Major NCD due to Alzheimer disease

Step 6 — ManagementOrder basic labs (TSH, B₁₂, CBC, CMP) to exclude reversible causes. Brain MRI will likely show medial temporal lobe/hippocampal atrophy. Initiate a cholinesterase inhibitor such as donepezil for symptomatic benefit. Consider adding memantine as the disease progresses to moderate-severe stages. Address caregiver support, safety planning (driving assessment, home safety evaluation), and advance care planning.

Start donepezil; exclude reversible causes; address safety and caregiver needs

SECTION 7

Delirium vs. Dementia vs. Depression — The Three D's

One of the most frequently tested differential diagnoses on USMLE Step 2 is distinguishing among delirium, dementia (major NCD), and depression (pseudodementia). These three conditions can all present with cognitive complaints in elderly patients, and exam questions often provide a clinical vignette requiring you to identify which one is responsible. Mastering the distinguishing features is essential for selecting the correct diagnosis and, critically, the correct next step in management.

The Three D's: Distinguishing delirium, dementia, and depression

Feature	Delirium	Major NCD (Dementia)	Pseudodementia (Depression)
Onset	Acute (hours to days)	Insidious (months to years)	Subacute (weeks); may coincide with depressive episode
Course	Fluctuating, often worse at night (sundowning)	Progressive and stable day-to-day	Variable; may fluctuate with mood
Attention	Severely impaired (hallmark)	Usually preserved until late stages	Variable; poor effort may mimic impairment
Consciousness	Altered (clouded, drowsy, or hyperalert)	Clear until late stages	Clear
Hallucinations	Common (often visual)	Less common (except LBD)	Rare
Patient's response to deficits	Variable; may be agitated or lethargic	Often unaware or minimizes deficits	"I don't know" answers; highlights own failures
Reversibility	Reversible if cause treated	Usually irreversible (exceptions: NPH, B₁₂, hypothyroid)	Reversible with antidepressant treatment
Key management	Identify and treat underlying cause; reorientation; avoid benzodiazepines	Etiology-specific pharmacotherapy; supportive care	SSRI or other antidepressant; psychotherapy

🧠 CLINICAL REASONING TIP

On the exam, pay close attention to the tempo of onset and the state of attention. If a patient develops confusion over hours to days with fluctuating attention and altered consciousness, the answer is almost certainly delirium regardless of what other details are provided. Think of delirium as the "emergency" in cognitive medicine—just as you would not attribute chest pain to GERD before ruling out MI, you should never diagnose dementia before excluding delirium. In the depressed elderly patient who says "I don't know" to every question but can perform tasks with encouragement, consider pseudodementia and trial an antidepressant.

SECTION 8

Connections to Advanced Topics & Emerging Concepts

As you progress from Step 2 to clinical practice, the field of neurocognitive disorders is evolving rapidly. Several advanced concepts are worth understanding because they increasingly appear on updated examinations and inform clinical decision-making. The NIA-AA (National Institute on Aging–Alzheimer's Association) research framework has proposed a shift from clinical syndromic diagnosis to a biomarker-based AT(N) classification system, where A = amyloid biomarkers, T = tau biomarkers, and N = neurodegeneration biomarkers. This allows detection of Alzheimer disease pathology before clinical symptoms emerge. Additionally, anti-amyloid monoclonal antibodies (lecanemab, donanemab) have recently shown modest clinical benefit in early symptomatic AD, marking the first disease-modifying therapies for this condition.

Current vs. emerging concepts in neurocognitive and developmental disorders

Current Step 2 Knowledge	Emerging / Advanced Concept
Clinical diagnosis of AD by history and cognitive testing	Biomarker-confirmed diagnosis via CSF Aβ₄₂/p-tau ratio or amyloid PET imaging; AT(N) research framework
Cholinesterase inhibitors and memantine for symptomatic treatment	Anti-amyloid immunotherapy (lecanemab, donanemab); monitoring for ARIA (amyloid-related imaging abnormalities)
ASD diagnosed by behavioral observation	Genome-wide association studies identifying hundreds of risk loci; eye-tracking and EEG biomarkers under investigation for early detection
ADHD treated with stimulants; diagnosis based on DSM-5 criteria	Recognition of adult ADHD as a persistent condition (not just childhood); updated research on non-stimulant agents like viloxazine
Reversible dementias identified by standard labs	Blood-based biomarkers (plasma p-tau217, plasma Aβ₄₂/₄₀ ratio) as screening tools to reduce need for invasive CSF sampling or expensive PET scans

For Step 2 purposes, you should focus on mastering the clinical diagnostic criteria and first-line management strategies outlined in previous sections. However, awareness of these advancing frontiers—particularly the anti-amyloid antibodies and their associated risks (ARIA-E and ARIA-H)—is increasingly relevant, as these topics are beginning to appear in updated question banks. The fundamental principle remains unchanged: accurate syndromic diagnosis followed by etiologic specification is the foundation upon which all emerging therapies are built.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A medical student asks why the DSM-5 abandoned the term "dementia" in favor of "major neurocognitive disorder." Which of the following best explains the rationale for this change?

PROBLEM 2 — BASIC CALCULATION

An 80-year-old man scores 22/30 on the MMSE. His daughter reports he occasionally forgets appointments but still pays his bills, shops independently, and manages his medications without assistance. Based on these findings, should this patient be classified as having major NCD, mild NCD, or no NCD? Explain your reasoning.

PROBLEM 3 — INTERMEDIATE

A 68-year-old man presents with a 6-month history of cognitive decline. His wife reports he has vivid visual hallucinations of children in the living room, his cognition seems to fluctuate dramatically throughout the day, and he has developed a shuffling gait. His psychiatrist prescribed haloperidol for the hallucinations, after which the patient developed severe rigidity, fever, and altered mental status. What is the most likely underlying diagnosis, and why was the haloperidol response predictable?

PROBLEM 4 — APPLIED

A 7-year-old boy is referred for evaluation because his second-grade teacher reports he cannot sit still, frequently interrupts classmates, and has difficulty completing assignments despite appearing intelligent. His parents note similar behavior at home and at soccer practice. His developmental milestones were normal. He makes good eye contact and has friends, though they sometimes find him "annoying." What is the most likely diagnosis, and what additional diagnostic criterion must be established? What is the first-line pharmacotherapy?

PROBLEM 5 — CRITICAL THINKING

A 75-year-old woman presents with a 2-month history of rapidly progressive cognitive decline, along with myoclonus, personality changes, and visual disturbances. MRI shows cortical ribboning on DWI sequences. Her family is concerned about Alzheimer disease. The attending physician suspects a different diagnosis. What is the most likely diagnosis, what confirmatory tests should be ordered, and how does the management differ from Alzheimer disease? Discuss the ethical considerations regarding prognosis disclosure.

SUMMARY

Summary

Neurocognitive disorders (NCDs) represent acquired cognitive decline from a prior level of functioning and are classified as major NCD (impaired functional independence) or mild NCD (preserved independence), followed by etiologic specification. The major etiologies include Alzheimer disease (insidious memory loss, Aβ plaques, tau tangles, treated with cholinesterase inhibitors), Lewy body dementia (fluctuating cognition, visual hallucinations, parkinsonism, neuroleptic sensitivity), vascular NCD (stepwise decline, vascular risk factors), and frontotemporal dementia (early personality change, onset often before 65). Always rule out delirium (acute onset, impaired attention, fluctuating consciousness) and reversible causes (B₁₂ deficiency, hypothyroidism, NPH, depression/pseudodementia) before diagnosing an irreversible NCD.

Neurodevelopmental disorders emerge during the developmental period and include intellectual disability (intellectual + adaptive deficits, onset in developmental period), autism spectrum disorder (social communication deficits + restricted/repetitive behaviors, managed with ABA and speech therapy), and ADHD (inattention ± hyperactivity-impulsivity, symptoms before age 12 in ≥ 2 settings, first-line treatment with stimulants). The diagnostic approach across both categories follows a systematic framework: characterize the cognitive or developmental deficits, determine severity and functional impact, and specify the underlying etiology to guide targeted management.